Home Newsfeeds Prelude Therapeutics Q3 EPS $(0.63) Up From $(0.66) YoY

Prelude Therapeutics Q3 EPS $(0.63) Up From $(0.66) YoY

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.63) per share. This is a 4.55 percent increase over losses of $(0.66) per share from the same period last year.

byBenzinga Newsdesk

November 14, 2022

1 minute read

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.63) per share. This is a 4.55 percent increase over losses of $(0.66) per share from the same period last year.

Earnings

SI-BONE Earnings Preview

By Benzinga Insights

April 28, 3:01 PM

SI-BONE (NASDAQ:SIBN) is set to give its latest quarterly earnings report on Monday, 2023-05-01. Here’s what investors need…

SIBN

Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal

By Vandana Singh

April 11, 12:42 PM

Eliem Therapeutics will acquire Tenet Medicines, focusing on advancing TNT119, an anti-CD19 antibody for autoimmune diseases. Strategic alternatives explored. $120 million private placement. Acquisition expected mid-2024.

ELYM

Coinbase Director Says Binance Can Completely Cover $4.3B DOJ Fine Without Selling Any Crypto — New Binance CEO Responds

By Mehab Qureshi

November 23, 2:50 AM

Coinbase’s director J Conor Grogan, on Wednesday said Binance has the necessary financial resources to settle with the US Department of Justice (DOJ) without liquidating its cryptocurrency holdings.

BTC